本页面由Tiger Trade Technology Pte. Ltd.提供服务

Aquestive Therapeutics Inc.

3.98
-0.0800-1.97%
盘后4.000.0201+0.51%18:20 EDT
成交量:265.89万
成交额:1,068.85万
市值:4.86亿
市盈率:-5.08
高:4.14
开:4.04
低:3.96
收:4.06
52周最高:7.55
52周最低:2.12
股本:1.22亿
流通股本:1.15亿
量比:1.46
换手率:2.31%
股息:- -
股息率:- -
每股收益(TTM):-0.7836
每股收益(LYR):-0.7836
净资产收益率:148.50%
总资产收益率:-33.92%
市净率:-14.42
市盈率(LYR):-5.08

数据加载中...

公司资料

公司名字:
Aquestive Therapeutics Inc.
交易所:
NASDAQ
成立时间:
2004
员工人数:
147
公司地址:
30 Technology Drive,Warren,New Jersey,United States
邮编:
07059
电话:
传真:
- -
简介:
Aquestive Therapeutics, Inc.于2004年1月在特拉华州成立。该公司是一家通过创新递送技术推进药物的制药企业,专注于开发侵入性标准疗法的替代方案。它开发包括用于过敏性休克的肾上腺素前药在内的专有候选药物,并拥有由其工厂生产的授权商业化产品。

董事

名称
职位
John Cochran
Vice Chairman of the Board
Keith J. Kendall
Chief Executive Officer, President and Director
Santo Costa
Chairman of the Board
James S. Scibetta
Director
Julie Krop
Director
Marco Taglietti
Director
Nancy Lurker
Director

股东

名称
职位
Keith J. Kendall
Chief Executive Officer, President and Director
Daniel Barber
Senior Vice President - Chief Operating Officer
A. Ernest Toth, Jr.
Interim Chief Financial Officer
Gary H. Slatko
Senior Vice President - Chief Medical Officer
Ken Marshall
Senior Vice President - Chief Commercial Officer
Lori J. Braender
Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
Peter Boyd
Senior Vice President - Business Process and Information Technology
Theresa Wood
Senior Vice President - Human Resources and Organizational Development
A. Mark Schobel
Chief Innovation and Technology Officer